Skip to main content

Drug Interactions between Funduscein and Univasc

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

moexipril fluorescein

Applies to: Univasc (moexipril) and Funduscein (fluorescein)

MONITOR: Beta-adrenergic blockers (including ophthalmic formulations) and ACE inhibitors may increase the severity and duration of acute anaphylactic reactions to fluorescein injection. In addition, anaphylaxis may be resistant to the usual treatment modalities. The mechanism is unknown.

MANAGEMENT: Patients should be closely monitored for signs of severe, acute hypersensitivity reactions during fluorescein injection, and facilities and equipment for resuscitation, cardiovascular support, and airway management should be immediately available. Clinicians should be aware that larger doses of epinephrine or other adrenergic agents may be required.

References

  1. (2006) "Product Information. AK-Fluor (fluorescein)." Akorn Inc

Switch to consumer interaction data

Drug and food interactions

Moderate

moexipril food

Applies to: Univasc (moexipril)

GENERALLY AVOID: Moderate-to-high dietary intake of potassium can cause hyperkalemia in some patients who are using angiotensin converting enzyme (ACE) inhibitors. In some cases, affected patients were using a potassium-rich salt substitute. ACE inhibitors can promote hyperkalemia through inhibition of the renin-aldosterone-angiotensin (RAA) system.

MANAGEMENT: It is recommended that patients who are taking ACE inhibitors be advised to avoid moderately high or high potassium dietary intake. Particular attention should be paid to the potassium content of salt substitutes.

References

  1. (2002) "Product Information. Vasotec (enalapril)." Merck & Co., Inc
  2. Good CB, McDermott L (1995) "Diet and serum potassium in patients on ACE inhibitors." JAMA, 274, p. 538
  3. Ray K, Dorman S, Watson R (1999) "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens, 13, p. 717-20

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer